CD28 and neoplasm: Interestingly, Guedan et al. recently demonstrated that substitution of a single amino acid in the CD28 co-stimulatory domain in mesothelin-targeting CAR T cells promoted anti-tumor control and reduced exhaustion and terminal differentiation in the CAR T cells [41].